泰国儿童肠道病毒A71型中和抗体纵向研究:出生至4岁
本研究在泰国曼谷对100名儿童从出生至48月龄纵向采集血清,用ELISA微量中和试验检测EV-A71中和抗体。结果显示,7月龄时血清保护率(中和抗体≥1:16)最低为9.0%,48月龄时仅37.1%儿童仍受保护。研究者建议将6月龄儿童作为疫苗接种的主要目标人群。
要点
- 7月龄时EV-A71中和抗体血清保护率最低(9.0%),因母体抗体消退。
- 48月龄时血清保护率仅37.1%,提示幼儿普遍易感。
- 建议将6月龄儿童作为EV-A71疫苗接种的主要目标人群。
核心结论
- 泰国儿童EV-A71中和抗体血清保护率在7月龄降至最低(9.0%),至48月龄仅37.1%儿童受保护。
- 研究提示6月龄儿童应作为EV-A71疫苗接种的主要目标人群。
研究设计与样本
- 纵向队列研究,纳入泰国曼谷King Chulalongkorn Memorial Hospital的100名儿童,2015至2020年采集血清。
- 采集分娩时母体血清及儿童出生(0月)和2、7、18、24、36、48月龄血清,用ELISA微量中和试验检测EV-A71中和抗体滴度。
主要发现
- 儿童0、2、7、18、24、36、48月龄的血清保护率(中和抗体≥1:16)分别为81.0%、60.0%、9.0%、10.0%、13.0%、17.0%、37.1%。
- 血清保护率在7月龄最低,归因于母体抗体消退,儿童免疫力随年龄增长而升高。
- 48月龄时不足40%儿童仍具血清保护。
关键数值与推荐
- 血清保护定义为EV-A71中和抗体滴度≥1:16。
- EV-A71疫苗候选株中已有三种在中国获批上市,目标人群为3岁以下儿童。
临床怎么用
- 应关注6月龄儿童EV-A71疫苗接种,以弥补母体抗体消退后的免疫空白。
- 血清学检测可用于估计社区累积感染率并指导疫苗接种时间安排。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thailand is one of the countries in the Asia-pacific region that has been most affected by the Enterovirus-A71 (EV-A71) epidemic. An individual who is susceptible to EV-A71 may also be infected asymptomatically, thus, a serological assay is a useful tool to estimate the cumulative incidence of infection in the community and to provide guidance for vaccination scheduling. There have been several candidate EV-A71 vaccines, of which three have been approved and licensed in China. The population target for EV-A71 vaccine is children younger than three years of age. In Thailand, there are limited data available on the seroprevalence of EV-A71 neutralizing (NT) antibodies and the timing of seroconversion in children. This study aims to investigate the seroprevalence and seroconversion rate of EV-A71 NT antibody in a cohort of Thai children. Sera were collected at the King Chulalongkorn Memorial Hospital in Bangkok, Thailand from 100 children between 2015 and 2020. Maternal sera were collected on the day of delivery. Serum samples from children were collected at birth (month 0) and at 2, 7, 18, 24, 36, and 48 months of age to test for EV-A71 NT antibody titers using an enzyme-linked immunosorbent assay (ELISA)-based microneutralization test. The seroprotection rate (NT antibody ≥1:16) in children at months 0, 2, 7, 18, 24, 36, and 48 was 81.0%, 60.0%, 9.0%, 10.0%, 13.0%, 17.0%, and 37.1%, respectively. The seroprotection rate was lowest at month 7 due to waning of the maternal antibody and the immunity of children increased with increasing age. At 48 months of age, less than 40% of children were seroprotected. Children at the age of 6 months should be considered a primary target for vaccination.
引用
- Puenpa J, Chansaenroj J, Auphimai C, et al. Neutralizing antibody against Enterovirus-A71 in Thai children: A longitudinal study from birth to age 4 years. Vaccine. 2020. PMID: 33067033. doi:10.1016/j.vaccine.2020.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。